Skip to Content


In the US, Vorapaxar (vorapaxar systemic) is a member of the drug class protease-activated receptor-1 antagonists and is used to treat Peripheral Arterial Disease, Prevention of Atherothrombotic Events and Thromboembolic Disorder.

US matches:



ATC (Anatomical Therapeutic Chemical Classification)


CAS registry number (Chemical Abstracts Service)


Chemical Formula


Molecular Weight


Therapeutic Category

Antiplatelet agent

Chemical Name

Ethyl[(1R,3aR,4aR,6R,8aR,9S,9aS)-9-{(1E)-2-[5-(3-fluorophenyl)pyridin-2-yl]ethen-1-yl}-1-methyl-3-oxododecahydronaphtho[2,3-c]furan-6-yl]carbamate (WHO)

Foreign Names

  • Vorapaxarum (Latin)
  • Vorapaxar (German)
  • Vorapaxar (French)
  • Vorapaxar (Spanish)

Generic Names

Brand Name

  • Zontivity
    Merck Sharp & Dohme Corp., United States


ISInofficial Synonym
JANJapanese Accepted Name
OSOfficial Synonym
PHPharmacopoeia Name
Rec.INNRecommended International Nonproprietary Name (World Health Organization)
USANUnited States Adopted Name
WHOWorld Health Organization

Further information on drug naming conventions: International Nonproprietary Names.

Important Notice: The international database is in BETA release. This means it is still under development and may contain inaccuracies. It is not intended as a substitute for the expertise and judgement of your physician, pharmacist or other healthcare professional. It should not be construed to indicate that the use of any medication in any country is safe, appropriate or effective for you. Consult with your healthcare professional before taking any medication.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.